利用蛋白质组学和代谢组学图谱区分代谢功能障碍与酒精相关性肝病(MetALD)
基于英国生物银行443,453名欧洲参与者数据,用弹性网络回归分析249种血浆代谢物和2,941种血浆蛋白,将MetALD患者分为酒精主导型(类ALD)和心血管代谢主导型(类MASLD)。10蛋白模型区分ALD与MASLD的AUC为0.93,酒精主导型MetALD患者死亡和肝硬化风险显著更高。
要点
- 10蛋白模型区分ALD与MASLD的AUC为0.93,优于代谢组学模型(AUC 0.86)。
- 蛋白质组模型加入年龄、性别、BMI、肝酶或代谢组信息后AUC未提升。
- 酒精主导型MetALD患者较心血管代谢主导型死亡和肝硬化风险显著更高,纤维化评分和分期更高。
核心结论
- 蛋白质组学亚型分析对MetALD有重要价值,有助于实现更个性化的治疗策略和改善预后评估。
研究设计与样本
- 研究分析英国生物银行443,453名欧洲参与者数据,包括34,147例MetALD、11,220例ALD和124,034例MASLD。
- 采用弹性网络回归基于249种血浆代谢物和/或2,941种血浆蛋白对ALD和MASLD进行分类,并进行多项敏感性分析。
- 将所得精简模型应用于MetALD患者,识别酒精主导组(分类为ALD)和心血管代谢主导组(分类为MASLD)。
- 使用Cox回归评估15年主要结局风险,包括心力衰竭、心肌梗死、卒中、肝硬化、肝细胞癌和死亡。
主要发现
- 单独代谢组区分ALD与MASLD的AUC为0.86,单独蛋白质组AUC为0.96。
- 10蛋白模型区分ALD与MASLD的AUC为0.93。
- 加入年龄、性别、BMI、肝酶或代谢组信息未提升蛋白质组模型的AUC。
- 酒精主导型MetALD患者较心血管代谢主导型MetALD患者死亡和肝硬化风险显著更高,纤维化评分和纤维化分期更高。
关键数值与推荐
- 代谢组模型区分ALD与MASLD的AUC为0.86。
- 蛋白质组模型区分ALD与MASLD的AUC为0.96。
- 10蛋白模型区分ALD与MASLD的AUC为0.93。
临床怎么用
- 临床医生可应用本研究开发的分类模型更准确地评估患者,并根据个体特征指导靶向治疗和预防措施。
- 作者认为蛋白质组亚型分析有助于MetALD的个性化治疗策略和预后评估。
局限性
- 研究依赖于自我报告的酒精消费量。
- 诊断标准的特异性存在局限。
- 需要在多样化队列中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Metabolic dysfunction- and alcohol-associated liver disease (MetALD) is a poorly understood condition that bridges cardiometabolic and alcohol-related pathological characteristics. We aimed to differentiate patients with MetALD whose molecular signatures more closely resemble either alcohol-related liver disease (ALD) or metabolic dysfunction-associated steatotic liver disease (MASLD), and to assess their relative risks of complications and mortality. METHODS: We analysed data from 443,453 European participants in the UK Biobank, including 34,147 with MetALD, 11,220 with ALD, and 124,034 with MASLD. Elastic net regression was used to classify ALD and MASLD based on 249 plasma metabolites and/or 2,941 plasma proteins, with multiple sensitivity analyses. We then applied the resulting concise model to patients with MetALD to identify an alcohol-predominant group (classified as ALD) and a cardiometabolic-predominant group (classified as MASLD). Finally, we evaluated their 15-year risk of major outcomes (heart failure, myocardial infarction, stroke, cirrhosis, hepatocellular carcinoma, and mortality) using Cox regression. RESULTS: The metabolome alone discriminated ALD from MASLD with an AUC of 0.86, while the proteome alone achieved an AUC of 0.96. Adding age, sex, BMI, liver enzymes, or metabolome information did not enhance the AUC of the proteome model. A 10-protein model differentiated ALD from MASLD with an AUC of 0.93. This model identified that patients with alcohol-predominant MetALD had significantly higher risks of mortality, and cirrhosis, along with elevated fibrosis scores and higher fibrosis stages, compared to patients with cardiometabolic-predominant MetALD. CONCLUSIONS: This study highlights the value of proteomic subtyping in MetALD, enabling more personalized treatment strategies and improved prognostic assessment. IMPACT AND IMPLICATIONS: This study underscores the critical importance of distinguishing subtypes of metabolic dysfunction- and alcohol-associated liver disease (MetALD) using proteomic data, providing a foundation for personalized treatment strategies. The findings hold significant relevance for healthcare providers, researchers, and policymakers by highlighting the differing risks associated with alcohol-predominant vs. cardiometabolic-predominant MetALD. Clinicians can apply the classification model developed in this study to more accurately assess patients and guide targeted therapies and preventive measures based on individual profiles. However, limitations of the study, such as reliance on self-reported alcohol consumption and the specificity of diagnostic criteria, necessitate further validation in diverse cohorts.
引用
- Liu J, Xiao S, Hu S, et al. Dissecting metabolic dysfunction- and alcohol-associated liver disease (MetALD) using proteomic and metabolomic profiles. J Hepatol. 2025. PMID: 40480315. doi:10.1016/j.jhep.2025.05.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。